Pasadena-based Genmark Diagnostics, a maker of molecular diagnostics equipment, lowered its initial public offering price to between $6.00 and $7.00 per share yesterday, down from an earlier anticipated initial public offering price of between $8.00 and $10.00 per share, according to a regulatory filing by the firm yesterday. The firm is looking to list on the NASDAQ Global Market as GNMK. GenMark's IPO is being underwritten by Piper Jaffray, William Blair & Company and ThinkEquity LLC.